Huperzine A

Generic name: Huperzia Serrata (Thunb.) Trev., Lycopodium Serratum (Thunb.).
Brand names: Brainmax, Chien Tseng Ta, Club Moss, Jin Bu Buan, Memorzine, Neuroflow, Qian Ceng Ta, She Zu Cao, Shi Song

Usage of Huperzine A

Huperzine A is approved for use as a drug for the treatment of Alzheimer disease in China; however, it is regulated as an herbal supplement in the United States.Alzforum 2009 Several firms (Solgar, Pharmavite, GNC, Kingchem, and NOW Foods) filed the required premarket notifications with the Food and Drug Administration between 1997 and 2000 for huperzine A products manufactured in China from natural sources.FDA 1997

Alzheimer disease

A Cochrane review of the effect of huperzine A in Alzheimer disease has been published, as well as other reviews.Desilets 2009, Kelley 2008, Li 2008 All reviews note the lack of quality long-term clinical trials to support definitive statements about a place in therapy for huperzine A, despite the numerous clinical studies being undertaken.Desilets 2009, Li 2008, Little 2008

Animal data

Animal and in vitro experiments have been conducted, and the mechanism of action for huperzine appears to be a combination of anticholinesterase activity and antiglutamate, antioxidant, and neuroprotective effects.Jiang 2003, Kelley 2008, Li 2008, Little 2008, Patil 2003, Peng 2006, Tang 2005, Wang 2006, Zhang 2008 Huperzine A crosses the blood-brain barrier more effectively than tacrine or donepezil and acts with greater potency than tacrine, physostigmine, or galanthamine.Lallement 2002, Little 2008 Huperzine A is selective for brain acetyl cholinesterase over plasma butyryl cholinesterase, which may account for its reported lower adverse effect profile in clinical studies.Cheng 1998, Little 2008

Clinical data

Based on limited data, some beneficial effects are attributed to huperzine A in Alzheimer disease, including an increase in general cognitive function, global clinical status, behavioral disturbances, and physical performance. Not all measurement scales found positive effects for huperzine A over placebo.Li 2008 The results of a US multicenter, phase 2 clinical trial (now closed), in which huperzine A was evaluated at 2 different doses versus placebo, are awaited.Aisen 2004, Little 2008 A systematic review and meta-analysis evaluating the effect of huperzine A for treatment of Alzheimer disease identified 20 randomized clinical trials that included over 1,800 participants; the quality of most trials had a high risk of bias. Regardless of disease course, disease severity, treatment preparation, dose, or duration, results showed favorable and sometimes significant effects on cognitive function and favorable effects on activities of daily living for huperzine A compared with placebo.Yang 2013 The American PsyChiatric Association (APA) guideline watch for the treatment of patients with Alzheimer disease and other dementias (2014) did not find enough definitive new evidence to change the 2007 guideline recommendations for alternative agents, including huperizine A.Rabins 2014

Other CNS effects

Dementia

High quality clinical trials are lacking; however, 1 review of 4 clinical trials found improvement against memory, dementia, and Alzheimer scales,Diamond 2003 while a Cochrane review found only 1 clinical trial meeting inclusion criteria in which no difference compared with placebo was found for vascular dementia.Hao 2009

Epilepsy

Anticonvulsant activity of huperzine A has been demonstrated in mice, and a pilot clinical study is being undertaken.Bialer 2007

Organophosphate antidote

Huperzine A's potent inhibition of cholinesterase has also made it a candidate for prevention of poisoning by the nerve agent soman and other organophosphates. In contrast to pyridostigmine, huperzine A crosses the blood-brain barrier and, therefore, may be effective in preventing seizures and other neuropathology caused by soman.Grunwald 1994, Wang 2006 Animal experiments have demonstrated activity against soman-induced seizures and mortality; however, clinical studies are lacking.Bajgar 2009, Eckert 2007, Gordon 2005, Grunwald 1994, Jiang 2003, Tonduli 2001

Parkinson disease

Protective effects have been demonstrated in mice models, but clinical trials are lacking.Chen 2007

Schizophrenia

A small (N = 19), open-label clinical study found improved cognitive effects for huperzine A over 12 weeks.Zhang 2007 Clinical trials on the use of huperzine in schizophrenia in the United States are being prepared for recruitment.Padala 2009, Woods 2009

Huperzine A side effects

In clinical trials, cholinergic side effects were noted, including hyperactivity, nasal obstruction, nausea, vomiting, diarrhea, insomnia, anxiety, dizziness, thirst, and constipation. One trial reported abnormalities in ECG patterns (cardiac ischemia and arrhythmia).Li 2008

The European Association for the Study of the Liver (EASL) clinical practice guideline for drug-induced liver injury (2019) recommends physicians consider herbal and dietary supplements as potential causative agents associated with liver injury (Level 4; Grade C), including Huperzine A (Lycopodium serratum; Jin Bu Huan).EASL 2019

Before taking Huperzine A

Information regarding safety and efficacy in pregnancy and lactation is lacking.

How to use Huperzine A

Huperzine A in pure form has been studied at oral dosages of 0.2 to 0.4 mg/day for Alzheimer disease. It has also been administered intramuscularly at 0.06 to 0.4 mg/day in dementia studies.Desilets 2009, Diamond 2003, Jiang 2003, Kelley 2008, Li 2008, Little 2008

In an open-label study among patients with schizophrenia, 0.3 mg/day for 12 weeks was used.Zhang 2007

The pharmacokinetics of huperzine A have been studied in healthy adult volunteers. A half-life of 288 minutes was reported, comparable with that of donepezil, while no tolerance was noted with multiple dosing.Little 2008 Transdermal patches have been tested in beagles.Wang 2006

Warnings

Symptoms of acute toxicity are similar to those of other cholinergic inhibitors and include muscular tremor, drooling, tears, increased bronchial secretions, and incontinence.Little 2008

The acute oral median lethal dose of huperzine A in rats has been reported as 4.6 mg/kg and as an intravenous dose of 0.63 mg.Ma 2007 One toxicological study reported increases in serum aminotransferases.Wang 2006 No pathological changes were found in histological studies of the liver, kidney, heart, lungs, or brain after 180 days of administration, and no mutagenicity or teratogenicity were found in rodent studies.Ma 2007

What other drugs will affect Huperzine A

Concomitant use of huperzine A with cholinesterase inhibitors could lead to potentiation of adverse reactions, although case reports are lacking.Kelley 2008

In vitro studies suggest potentiation of huperzine A by the green tea polyphenol epigallocatechin-3-gallate.Zhang 2009

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.